Company Overview
Anebulo Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions within the United States market. The firm functions within the broader Healthcare sector and specifically the Biotechnology industry, a space characterized by high research and development costs and significant regulatory hurdles before products reach commercialization. The company's current scale is defined by a market capitalization of $36.18M, a reported annual revenue of N/A, and a workforce consisting of 2 employees. These valuation and operational metrics indicate that the company is in an early-stage development phase where limited capital resources are concentrated on advancing its lead product candidate, the selonabant, rather than on generating substantial commercial revenue or expanding a large employee base. The absence of reported revenue alongside a market cap in the tens of millions suggests that the company's primary asset is its intellectual property and clinical pipeline rather than established sales channels or a mature product portfolio.
Financial Health
The company reports a Net Income (TTM) of $-7,978,748, while Revenue (TTM) and EBITDA are both listed as N/A, revealing a cost structure dominated by non-revenue expenses typical of early-stage biotechnology firms. The significant negative net income combined with zero reported revenue indicates that the company is burning cash through research and development activities without yet generating commercial sales to offset these substantial expenditures. Free Cash Flow stands at $-3,774,629, which signifies that the company is utilizing its cash reserves to fund operations and development efforts rather than distributing funds or achieving positive cash generation. This negative free cash flow position requires continuous external financing or the depletion of existing assets to sustain current R&D and administrative functions. The margins profile shows a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, all of which reflect the pre-commercialization status where no sales have been recorded to generate profitability. Regarding liquidity and leverage, the company holds $9.04M in cash against N/A in debt, resulting in a Debt to Equity ratio of N/A. The absence of recorded debt alongside a substantial cash balance suggests a conservative balance sheet structure that relies on equity financing rather than leverage to fund its activities. The Current Ratio is 6.24, a figure that indicates strong short-term liquidity relative to current liabilities, providing the company with ample resources to cover immediate obligations. Return on Equity is -69.7% and Return on Assets is -45.0%, metrics that reveal management is currently focused on value creation through asset accumulation and development rather than immediate profit generation. These negative return figures are consistent with the industry norms for clinical-stage companies that have not yet achieved commercial revenue milestones.
Valuation Assessment
The valuation metrics for Anebulo Pharmaceuticals, Inc. show a P/E Ratio (TTM) of N/A and a Forward P/E of -1.36, implying that traditional earnings-based valuation methods are not applicable due to the lack of positive earnings and the forward-looking estimate reflecting a negative earnings trajectory. The Price to Book ratio is 4.60, which indicates that the market values the company's equity at a significant premium over its accounting book value, reflecting investor confidence in the potential success of its clinical pipeline and intangible assets. The Price to Sales ratio is N/A and the EV/EBITDA is N/A, suggesting that alternative valuation metrics relying on sales or operating earnings are not yet applicable for a company with no reported revenue. The stock price has fluctuated between a 52-Week High of $3.42 and a 52-Week Low of $0.30, establishing a wide trading range that highlights the high volatility often associated with small-cap biotechnology stocks. The Beta is -0.70, a negative value that indicates the stock's price volatility moves inversely to the broader market or is decoupled from standard market movements, presenting a unique risk profile for portfolio diversification.
Growth & Income
The company reports a Revenue Growth (YoY) of N/A and an Earnings Growth (YoY) of N/A, indicating that historical growth rates cannot be calculated as the firm has not yet established a baseline of commercial revenue or consistent earnings. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm reinvests all available resources and retained earnings directly back into its research, development, and clinical trial programs to advance the selonabant candidate. This strategy prioritizes long-term product development and market expansion over providing current income to shareholders, which is a standard approach for clinical-stage biotechnology companies. The overall growth and income profile is characterized by zero current income generation and undefined historical growth rates, with the company's value proposition relying entirely on the potential future commercialization of its drug candidates.